NICE approves rivaroxaban for DVT and recurrent VTE

The direct factor Xa inhibitor rivaroxaban has been recommended for NHS use in two new indications.

It is estimated that there will be over 46,000 cases of acute DVT in England and Wales during 2012 | SCIENCE PHOTO LIBRARY
It is estimated that there will be over 46,000 cases of acute DVT in England and Wales during 2012 | SCIENCE PHOTO LIBRARY

NICE has recommended rivaroxaban (Xarelto) as an option for treating deep vein thrombosis (DVT) and for preventing recurrent DVT and pulmonary embolism after a diagnosis of acute DVT in adults.

The anticoagulant can also be prescribed on the NHS to prevent stroke and systemic embolism in patients with non-valvular atrial fibrillation, and to prevent venous thromboembolism (VTE) following total hip or knee replacement. 

Further details

NICE guidance on rivaroxaban in DVT

Further information:

View Xarelto drug record

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

A woman wearing a white vest as a blue-gloved hand of a healthcare professional are seen injecting a vaccine.

'Nocebo' effect may cause two-thirds of COVID-19 vaccine reactions, study suggests

Two-thirds of adverse reactions reported with the COVID-19...

An elderly woman with one arm in a plaster cast sits resting both hands on her walker

Doctors urge NICE to reverse decision on new osteoporosis drug

More than NHS 100 clinicians have called on NICE to...

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

Image of both strengths of Seffalair Spiromax inhaler side by side.

New salmeterol/fluticasone dry powder inhaler for asthma

Seffalair Spiromax is the sixth dry powder salmeterol/fluticasone...